The effect of a single dose of BNT162b2 vaccine on the incidence of severe COVID-19 infection in patients on chronic hemodialysis: a single-centre study

Introduction In this single-centre retrospective observational study, the 8-week safety and the efficiency of a single dose of BNT162b2 vaccine was studied in 83 HD patients. Methods All clinically stable adult ESRD patients on chronic HD for at least 4 weeks were screened for participation in the s...

Full description

Saved in:

Bibliographic Details
Published in:	Clinical and experimental nephrology Vol. 26; no. 1; pp. 54 - 58
Main Authors:	Cserep, Gabor, Morrow, David, Latchford, Karen, Jesset, Rachael, Dosa, Agnes, Kirmizis, Dimitrios
Format:	Journal Article
Language:	English
Published:	Singapore Springer Singapore 01-01-2022 Springer Nature B.V
Subjects:	Adult Aged Aged, 80 and over BNT162 Vaccine - administration & dosage BNT162 Vaccine - adverse effects Chronic infection Coronaviruses COVID-19 COVID-19 - diagnosis COVID-19 - epidemiology COVID-19 - prevention & control COVID-19 vaccines England - epidemiology Female Hemodialysis Humans Hypersensitivity Immunization Immunization Schedule Incidence Infections Injections, Intramuscular Kidney Failure, Chronic - diagnosis Kidney Failure, Chronic - epidemiology Kidney Failure, Chronic - therapy Male Medicine Medicine & Public Health Middle Aged Nephrology Original Original Article Patient Safety Patients Pneumonitis Renal Dialysis Retrospective Studies Risk Assessment Severity of Illness Index Time Factors Treatment Outcome Urology Vaccination Vaccines Young Adult England COVID-19 BNT162b2 vaccine Hemodialysis
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Introduction In this single-centre retrospective observational study, the 8-week safety and the efficiency of a single dose of BNT162b2 vaccine was studied in 83 HD patients. Methods All clinically stable adult ESRD patients on chronic HD for at least 4 weeks were screened for participation in the study. Exclusion criteria for enrollment in the study included a medical history of COVID-19 infection within the last 12 weeks or delivery of both vaccine doses less than 8 weeks apart from each other. The same patients during the 8-week period that preceded the vaccination served as controls of themselves. The vaccine was administered intramuscularly in the deltoid muscle, on a dialysis day, at least 30 min either pre- or post-dialysis. The primary end-point of the study was severe COVID-19 infection, and/or death due to COVID-19 pneumonitis. Furthermore, all vaccinated patients were scrutinized for any local or systemic reactions within the first 7 days post-vaccination. Results Amongst 113 adult HD patients in our Unit, in total 83 patients had the first 30 μg dose of the BNT162b2 vaccine and were considered eligible to be included in the study. The 8-week survival rate was 91% for the controls and 100% for the vaccine group. No life-threatening allergic reaction or other side-effect was observed post-vaccination. Conclusion The BNT162b2 vaccine can be safely used in HD patients and seems to offer significant protection against the infection even after the first vaccine dose.
Bibliography:	ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Undefined-1 ObjectType-Feature-3 content type line 23
ISSN:	1342-1751 1437-7799
DOI:	10.1007/s10157-021-02118-4